Inflammatory Breast Neoplasms

• 

  Subject Areas on Research

  • A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. 
  • Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. 
  • Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. 
  • Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. 
  • Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. 
  • Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. 
  • Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). 
  • ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. 
  • Immunologic targeting of FOXP3 in inflammatory breast cancer cells. 
  • Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies. 
  • Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. 
  • Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. 
  • Photothermal ablation of inflammatory breast cancer tumor emboli using plasmonic gold nanostars. 
  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. 
  • Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. 
  • Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. 
  • Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. 
  • Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. 
  • What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? 
  • X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. 
  • XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Chair, Department of Pharmacology & Cancer Biology, Duke Innovation & Entrepreneurship